IMU Ann: Imugene appoints experienced life sciences CFO Mike Tonroe
Price Sensitive: N
Date: 18th Jul 2022, 9:35am
>>> Read announcement:
Google: IMU Market Announcements
Mike Tonroe's appointment bodes very well for what's around the corner! IMU have managed their finances very carefully to this point, and have plenty of cash in the bank - more than enough to run their multiple clinical trials. And they are not in the habit of adding to the payroll simply for appearances. So Mike's appointment as CFO means just one thing to dopey old me. They feel the need for an experienced financial dude to handle what's likely to happen when the upcoming trial results become known! And Mike sounds like the perfect person for such a job.
It's well known that many existing oncology drugs are nearing the end of their patent protection. That makes IMU's new offerings super attractive, don't you think? There are lots of companies flush with cash from selling covid vaccines around the world. It's not hard to imagine that if one of these companies makes a play for one of IMU's cancer treatments, the others won't sit back and let them have it for a song!
I reckon we're in for a very interesting time ahead - one that should bring much relief to cancer sufferers. It does feel good to be a shareholder!
Jeff
